About US
Contact us
-
Mesa Labs Acquires Assets of CoaChrom Diagnostica and bioTRADING BeneluxMesa Laboratories' subsidiary Mesa France is acquiring assets and liabilities of two European distributors. These acquisitions involved CoaChrom Diagnostica of Austria and bioTRADING Benelux of the N2016/7/19
-
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's EnbrelAmgen ($AMGN) is spending Tuesday making its case for a biosimilar approval before an FDA advisory committee. But come Wednesday, it’ll be Novartis’ ($NVS) Sandoz doing the same with a copy of an Amge2016/7/18
-
Shire's new dry-eye approval means it's time for an Allergan showdownShire($SHPG) has the approval it’s been waiting for--and the label it wanted, too. Late Monday, the FDA green-lighted dry-eye candidate lifitegrast, to be marketed under the brand name Xiidra. And th2016/7/18
-
FDA grants approval for Pfizer’s Prevnar 13 to prevent pneumococcal pneumoniaAmerican pharmaceutical company Pfizer has received the US Food and Drug Administration (FDA) approval for its Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) to prev2016/7/15
-
UK NICE denies use of Bristol-Myers’ nivolumab to treat kidney cancerAmerican pharmaceutical company Bristol-Myers Squibb has received a recommendation from the UK National Institute for Health and Care Excellence (NICE) that could deny the use of nivolumab to treat Na2016/7/15
-
Allergan’s Belkyra receives positive opinion from Swedish MPA to treat double chinPharmaceutical company Allergan has received a positive opinion from Sweden's Medical Products Agency (MPA) for Belkyra (deoxycholic acid) to treat moderate to severe convexity related to submental fa2016/7/14
-
Newest Imbruvica 'breakthrough' tag gives J&J, AbbVie hope for expansion outside blood cancersJohnson & Johnson and AbbVie have been charging hard to rack up additional indications for star med Imbruvica in hematologic cancers. But with the med’s latest breakthrough designation, there’s ho2016/7/14
-
Pfizer's bococizumab may hit the PCSK9 market just in timPfizer tallied a couple more wins in its lineup of late-stage PCSK9 trials: Bococizumab, a would-be competitor to similar meds from Amgen, Sanofi and Regeneron, beat placebo at pulling down cholestero2016/7/13
-
With no time to waste, AstraZeneca sues FDA to block Crestor copycatsAstraZeneca isn’t waiting for the FDA to answer its citizen petition to block Crestor generics. With time short before the arrival of a slew of cheap rivals to its big-selling statin, the company has2016/7/13
-
NICE releases ACD to not recommend AstraZeneca’s Tagrisso for NSCLC treatmentUK's National Institute for Health and Care Excellence (NICE) has published an Appraisal Consultation Document (ACD) for British pharmaceutical company AstraZeneca's Tagrisso (osimertinib). Tagrisso2016/7/12